We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Aggressive Prostate Cancer Determined by Diagnostic Tool

By LabMedica International staff writers
Posted on 15 May 2012
A nanoparticle test has been developed that distinguishes prostate cancer from normal and benign conditions and has the potential to predict the aggressiveness of prostate cancer quantitatively. More...


A serum gold particle nanoparticle (AuNP) adsorption assay may answer the biggest challenge for cancer biomarker discovery and early cancer detection when the amount of specific molecules that are released from the tumor to the blood is very small.

Scientists at the University of Central Florida (Orlando, USA) who conducted the assay mixed a serum solution with a citrate-protected AuNP solution and the average particle size of the AuNP solution before and after sample incubation is measured by dynamic light scattering (DLS). The gold nanoparticles detect a specific chemical reaction between a prostate tumor and the human immunoglobulin G (IgG), an abundant protein circulating in the blood.

The IgG likes to stick to the surface of the gold nanoparticles to form a protein corona. This corona can be detected by the DLS technique. The investigators found that when cancer cells are present, they can destroy the IgG in the blood, and this specific interaction is picked up by the gold nanoparticles. This simple test can determine quantitatively how aggressive the prostate tumors are and the likelihood they will metastasize. The team tested out the technique on human tissue samples.

The average diameter of the citrate AuNP is 100 nm and the concentration of the nanoparticle is 10 pM and was obtained from Ted Pella Inc. (Redding, CA, USA). Particle size analysis of the assay solutions was conducted using an automatic DLS instrument, NDS1200, from Nano Discovery Inc. (Orlando, FL, USA). Qun Huo PhD, the lead investigator on the project, said, "Our nanoparticles not only seek out a chemical reaction that is specific to prostate cancer, they can also tell us how aggressive the cancerous cells are likely to be, which can give doctors better information to treat their patients." The study was published on March 9, 2012, in the Journal of Translational Medicine.

Related Links:

University of Central Florida


Ted Pella Inc.

Nano Discovery Inc



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.